1. Home
  2. GLMD vs BIAF Comparison

GLMD vs BIAF Comparison

Compare GLMD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$4.37

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.40

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLMD
BIAF
Founded
2000
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.5M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
GLMD
BIAF
Price
$4.37
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
115.9K
1.8M
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.41
$0.23
52 Week High
$5.45
$13.50

Technical Indicators

Market Signals
Indicator
GLMD
BIAF
Relative Strength Index (RSI) 86.02 40.77
Support Level $0.56 $0.33
Resistance Level N/A $1.45
Average True Range (ATR) 0.19 0.07
MACD 0.45 0.02
Stochastic Oscillator 75.89 10.24

Price Performance

Historical Comparison
GLMD
BIAF

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: